Randomized Trials and IMRT: Overkill or Overdue?

S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 22 de octubre del 2003

Share article


Moderator: Theodore L. Phillips, MD., University of California, San Francisco

Soeren M. Bentzen, PhD., DSc., Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom

  • IMRT is an advanced technology for radiation therapy (RT), using non-uniform radiation beam intensities incident upon the patient.
  • From a dosimetric and operational point of view, IMRT is superior to forward-planned treatment, including 3DCRT.
  • Despite, the dosimetric advantages of IMRT, the question remains: Will IMRT improve clinical outcomes?
  • Various schemes for levels of clinical evidence support of a treatment have been proposed; most define level I evidence as large, adequately powered randomized trials or a metaanalysis supporting the use of treatment. Level IV evidence can be defined as single-arm non-randomized trials comparing results to historical controls.
  • Clinical outcome data for IMRT is almost solely level IV evidence.
  • Level IV evidence does not equal Level I evidence.
  • As a historical example, the use of continuous hyperfractionated accelerated radiation therapy (CHART) for head and neck (H&N) cancers was studied and compared to historical controls treated with conventionally fractionated RT matched for tumor site, T stage, and N stage. These comparisons showed improved outcome with CHART; however, a randomized trial of CHART showed no difference compared to conventional fractionation.
  • The above example demonstrates the importance of randomized trials.
  • In conclusion, evidence-based IMRT is not showing improved distribution but a therapeutic gain; it is not showing decreased toxicity, but doing so without compromising local control, it is not increasing local control, but doing so without increasing toxicity.


News
ASTRO: Hypofractionated IMRT Practical Approach in Prostate CA

Sep 30, 2011 - Hypofractionated intensity modulated radiotherapy (IMRT) and conventional IMRT therapy are equally effective in decreasing recurrence of intermediate- to high-risk prostate cancer at five years, according to a study presented at the anual meeting of the American Society for Radiation Oncology, held from Oct. 2 to 6 in Miami Beach.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información